Tag: SYMX

Blue Horseshoe Stocks: AAPL Update & More

Apple Inc. AAPL – Options

We once again found a way to leverage AAPL’s current uptrend to our advantage yesterday using the options chain. Just to refresh people’s memories, the idea we highlighted in our premarket report was to monitor Weekly Calls in the $130-132 range.

As AAPL pressed to a daily high of $133.13 we saw significant action in both the $131 and $132 Calls. The $131’s dipped as low as 3.60 before running to a subsequent high of 4.50, for an intraday move equaling 25%, and the $132’s made a nice spike from 3.10-3.88; also a 25% swing.

Pazoo, Inc. PZOO

We also want to mention the performance of PZOO which surged to a new high of .0204 yesterday. In the video charts we’ve published on PZOO over the past couple of trading days, we mentioned that the 200DMA of .0204 should act as key resistance, and that’s where yesterday’s intraday run topped out. From a morning low of .0177, it marked a 15% jump.

From our observed low of .0049 on April 6th, PZOO’s new high marked an overall increase of 316% We stated this week that we want to see the stock maintain support in the channel between .011-.014, and that remains true today.

Any way you slice it, PZOO has performed admirably in the month of April.


Netlist, inc. NLST

Hitting our scanner this morning is a stock that has been in a steady downtrend for quite some time, which is gapping up in the premarket on the heels of an early PR linking the company to LG Electronics.

NLST has spent the better part of the last three months bottoming out, and the stock just set a new 52-week low yesterday. This is exactly the type of play that we like to monitor, as it gets kicked up off of annual lows.


Other Notable Gainers From Yesterday’s Watchlist

We’d also like to highlight two other plays that appeared in yesterday’s premarket report that provided opportunities for our readers.

SYMX traded in a daily range from 1.65-2.10, an increase of 27%

CANF rose from a low of 2.61 to hit 3.57; an intraday move of 37%

Extended Watchlist:
AGEN, CLDN, AEZS, VSR, TSLA

Blue Horseshoe Stocks: Another Big Move From PZOO & More

Pazoo, Inc. PZOO

We’ve been more than pleased with the performance of PZOO this month after coming back to follow it closely on the 1st. We’ve tracked it every step of the way as it has made its way from a subpenny low of .0049 (04/06) and streaked to impressive new highs following our morning report on Friday.

PZOO started from a daily low of .0123 and broke the key level of resistance at .014 (we pointed out in a video we published Friday afternoon) before running to close at its high of day at .016. It represented an intraday move of 30% and an overall increase of 227% over our observed low earlier this month.

We’ve drawn up another video demonstrating some of the PZOO chart highlights, and we’ve linked that below. In addition, Pazoo released another key PR this morning, and we’ve provided a link to that as well. We’d suggest our readers explore both links!

 

WHIPPANY, N.J., April 27, 2015 (GLOBE NEWSWIRE) — Pazoo, Inc. (OTC Pinks:PZOO) (German WKN#:A1J3DK), is pleased to announce that as of today and more than a week ahead of schedule, the company has completely repaid the total of its obligations on its Convertible Promissory Note to Eastmore Capital LLC. >> FULL PR

Options Trading

Apple Inc. AAPL & Amazon.com, Inc. AMZN were the subject of our options-trading ideas on Friday. In both cases we mentioned an interest in looking for dip-and-rip scenarios, and both stocks did indeed follow suit. Our ideas for trading Weekly Calls in each would have paid off handsomely for anyone who took the initiative.

AAPL reports earnings today, and is gapping up significantly in premarket trading so we’re going to be on the lookout for opportunities in the Weekly $130-132 Range as we kick off a fresh trading week.

Molycorp, Inc. MCP

Some of our regular followers will recall our entering MCP into our reports on April 8th, and regularly revisiting it since then. Following our initial alert on this play we observed a low of .48, and the stock continues to press to new highs.

On Friday, MCP hit a new high of 1.04, which marks an impressive 117% swing from this stock inside of the past two weeks.

Enzon Pharmaceuticals, Inc. ENZN

We flagged ENZN for tracking on Thursday, after noting that it is another stock in which billionaire investor Carl Icahn has a stake. The stock made notable 16% intraday move on Friday, and we want to keep it on continual watch moving forward.

We covered VLTC recently as it made a truly historic move as a result of Icahn’s involvement, and are anxious to monitor any stock that draws the interest of such a high-profile investor.

Extended Watchlist:
SYMX, CANF, IBIO, WIN, CPRX, UEC

Blue Horseshoe Stocks: LXRP News Update & FDA-Related Plays

Lexaria Corp. LXRP

Following our initial report on LXRP yesterday, the stock had a productive session as it traded in a range from .095 to a high of .108, an intraday gain of 14% on roughly 2.5X the monthly average volume. It closed at .102 holding more than half of the day’s gains, which is generally a good sign.

We promised to relay any further updates regarding the current status of LXRP, and sure enough the company published a fresh PR this morning containing another major development. It relates to the sale of Lexaria’s domestic oil assets, which we mentioned in yesterday’s report, becoming final with all funds received. It provides LXRP with a cash infusion of $1.4M which will facilitate a clearing of all debt currently on the books, as well as advance the company’s plans to release a CBD-infused tea (infusion method is patent pending) via a new online sales portal. With the rate at which LXRP has been executing its strategies, we expect to hear about the opening of that website any day now.

KELOWNA, BC / ACCESSWIRE / December 10, 2014 / Lexaria Corp. (LXRP) (CSE:LXX) (the “Company” or “Lexaria”) is pleased to announce the sale of all its Belmont Lake oil assets for $1.4 million in cash has closed and all money received. Lexaria congratulates the new owners for having purchased a fine asset. >> FULL PR

FDA-Related News

We caught a couple of FDA news plays on this morning’s scan that we’ll want to keep an eye on:

ARCA BioPharma, Inc. ABIO has reported that the FDA “has granted orphan drug designation to rNAPc2 as a potential treatment of viral hemorrhagic fever post-exposure to Ebola virus.” >> VIEW PR

Cytori Therapeutics, Inc. CYTX announced that the FDA granted approval “for a pivotal clinical trial, named the ‘STAR’ trial, to evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 patients in the United States.” >> VIEW PR

Extended Watchlist:
 CYRN, SYMX, SNSS